Screener
Amgen AMGN Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Aranesp | $352M-1.9% | $311M-8.5% | $333M+8.1% | $357M+5.9% | $359M+3.2% | |
| BLINCYTO | $472M+22.9% | $415M+12.2% | $413M+8.4% | $392M+19.9% | $384M+45.5% | |
| ENBREL | $580M-4.0% | $320M-37.3% | $532M-47.6% | $580M-29.7% | $604M-33.6% | |
| EVENITY | $714M+37.8% | $562M+27.1% | $599M+39.0% | $541M+35.6% | $518M+32.5% | |
| IMDELLTRA/IMDYLLTRA | $288M+115% | $258M+219% | —— | —— | $134M— | |
| KRYSTEXXA | $400M+14.6% | $255M+8.1% | $435M+25.7% | $320M+3.2% | $349M+18.7% | |
| KYPROLIS | $314M-16.9% | $330M+1.9% | $351M-5.6% | $359M-5.0% | $378M+0.3% | |
| Nplate | $430M+16.5% | $412M+31.6% | $385M+14.2% | $457M+0.2% | $369M+6.6% | |
| Otezla | $491M-20.6% | $431M-1.4% | $625M+0.2% | $585M+3.7% | $618M+13.6% | |
| Other products | $1.7B+23.0% | $1.53B+3.6% | $2.07B+32.2% | $1.85B+36.0% | $1.38B+4.1% | |
| Prolia | $759M-32.4% | $727M-33.8% | $1.05B-9.5% | $1.14B+9.0% | $1.12B-3.7% | |
| Repatha | $953M+36.9% | $876M+33.5% | —— | $794M+40.0% | $696M+30.8% | |
| TEPEZZA | $576M+14.1% | $490M+28.6% | $457M-0.7% | $560M+14.8% | $505M+5.4% | |
| TEZSPIRE | $486M+42.1% | $343M+20.4% | $474M+60.1% | $377M+40.1% | $342M+46.2% | |
| UPLIZNA | $335M+90.3% | $262M+188% | —— | —— | $176M— | |
| Vectibix | $338M+10.8% | $287M+7.5% | $319M+29.7% | $284M+0.7% | $305M+13.0% | |
| XGEVA | $352M-33.8% | $411M-27.4% | $447M-20.3% | $539M-0.4% | $532M-5.3% |
FAQ
- How does Amgen break its business down?
- Amgen (AMGN) reports total revenues by product across 18 parts — Aranesp, BLINCYTO, ENBREL, EVENITY and IMDELLTRA/IMDYLLTRA. Each is extracted from the segment footnotes and tracked over time.
- Where does Amgen's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amgen's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
